Interconnected microphysiological systems for quantitative biology and pharmacology studies CD Edington, WLK Chen, E Geishecker, T Kassis, LR Soenksen, ... Scientific reports 8 (1), 4530, 2018 | 424 | 2018 |
Combining the ‘bottom up’and ‘top down’approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data N Tsamandouras, A Rostami‐Hodjegan, L Aarons British journal of clinical pharmacology 79 (1), 48-55, 2015 | 270 | 2015 |
Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies N Tsamandouras, WLK Chen, CD Edington, CL Stokes, LG Griffith, M Cirit The AAPS journal 19, 1499-1512, 2017 | 190 | 2017 |
Quantitative assessment of population variability in hepatic drug metabolism using a perfused 3D human liver microphysiological system N Tsamandouras, T Kostrzewski, CL Stokes, LG Griffith, DJ Hughes, ... Journal of Pharmacology and Experimental Therapeutics 360 (1), 95-105, 2017 | 105* | 2017 |
Capsaicin-evoked cough responses in asthmatic patients: evidence for airway neuronal dysfunction I Satia, N Tsamandouras, K Holt, H Badri, M Woodhead, K Ogungbenro, ... Journal of Allergy and Clinical Immunology 139 (3), 771-779. e10, 2017 | 94 | 2017 |
Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population‐modeling approach N Tsamandouras, G Dickinson, Y Guo, S Hall, A Rostami‐Hodjegan, ... Clinical Pharmacology & Therapeutics 96 (1), 90-100, 2014 | 75 | 2014 |
Development and application of a mechanistic pharmacokinetic model for simvastatin and its active metabolite simvastatin acid using an integrated population PBPK approach N Tsamandouras, G Dickinson, Y Guo, S Hall, A Rostami-Hodjegan, ... Pharmaceutical research 32, 1864-1883, 2015 | 66 | 2015 |
Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction … M Gertz, N Tsamandouras, C Säll, JB Houston, A Galetin Pharmaceutical research 31, 2367-2382, 2014 | 57 | 2014 |
Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical … AR Saxena, JP Frias, LS Brown, DN Gorman, S Vasas, N Tsamandouras, ... JAMA Network Open 6 (5), e2314493-e2314493, 2023 | 52 | 2023 |
Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population N Tsamandouras, Y Guo, T Wendling, S Hall, A Galetin, L Aarons Pharmacogenetics and Genomics 27 (1), 27-38, 2017 | 21 | 2017 |
Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data T Wendling, N Tsamandouras, S Dumitras, E Pigeolet, K Ogungbenro, ... The AAPS Journal, 1-14, 2015 | 21 | 2015 |
Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations N Tsamandouras, T Wendling, A Rostami-Hodjegan, A Galetin, L Aarons Journal of pharmacokinetics and pharmacodynamics 42 (4), 349-373, 2015 | 15 | 2015 |
Physiologically relevant, humanized intestinal systems to study metabolism and transport of small molecule therapeutics A Sawant-Basak, AD Rodrigues, M Lech, R Doyonnas, M Kasaian, ... Drug Metabolism and Disposition 46 (11), 1581-1587, 2018 | 14 | 2018 |
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: a 12‐week, randomized, placebo … AR Saxena, JP Frias, DN Gorman, RN Lopez, N Andrawis, ... Diabetes, Obesity and Metabolism 25 (10), 2805-2814, 2023 | 13 | 2023 |
Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure–response analysis N Tsamandouras, S Duvvuri, S Riley Journal of Pharmacokinetics and Pharmacodynamics 46 (6), 605-616, 2019 | 3 | 2019 |
Once-daily oral small molecule GLP-1R agonist PF-07081532 robustly reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with … C Buckeridge, N Tsamandouras, S Carvajal-Gonzalez, LS Brown, ... Diabetologia 65 (SUPPL 1), S60-S60, 2022 | 2 | 2022 |
Development and applications of physiologically-based pharmacokinetic models for population data analyses N Tsamandouras PQDT-UK & Ireland, 2015 | 2 | 2015 |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and … SI Danto, N Tsamandouras, P Reddy, S Gilbert, J Mancuso, K Page, ... The Journal of Clinical Pharmacology 64 (5), 529-543, 2024 | 1 | 2024 |
Oral small molecule GLP-1 receptor agonist danuglipron (PF-06882961) results in glucose lowering and body weight loss over 16 weeks in adults with type 2 diabetes AR Saxena, J Frias, LS Brown, DN Gorman, N Tsamandouras, ... DIABETOLOGIA 65 (SUPPL 1), S302-S302, 2022 | 1 | 2022 |
Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple … C Buckeridge, N Tsamandouras, S Carvajal‐Gonzalez, LS Brown, ... Diabetes, Obesity and Metabolism, 2024 | | 2024 |